Phase I- II Study of in Vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for the Treatment of Steroid-refractory Acute Graft-versus-host Disease
Phase of Trial: Phase I/II
Latest Information Update: 17 Jul 2013
At a glance
- Drugs Azacitidine (Primary) ; Interleukin-2 (Primary) ; Cyclophosphamide; Sirolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 01 Jul 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Oct 2011 New trial record